In another study, it was found that PYGL was up-regulated in cisplatin-resistant human ovarian carcinoma cell line SKOV3/DDP when compared to cisplatin-sensitive human ovarian carcinoma cell line SKOV3 (Xu et al., 2018). Here, PYGL is linked to ovarian carcinoma.